Physician profile
Brian J Feaver
NPI 1891716858
$911.71
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $204 · 2021: $79.23.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $157.11 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.06 | 2019-2020 | |
| Allergan, INC. | $79.16 | 2019-2020 | |
| Amarin Pharma, INC. | $68.70 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $64.18 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $45.23 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $41.16 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $40.71 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.12 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.95 | 2019 | |
| Pfizer INC. | $30.03 | 2019-2020 | |
| Nevro Corp. | $28.99 | 2019 | |
| Merck Sharp & Dohme LLC | $25.77 | 2019 | |
| Glaxosmithkline, LLC. | $25.17 | 2019-2020 | |
| Radius Health, INC. | $24.76 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $18.94 | 2019 | |
| Abbvie INC. | $17.16 | 2021 | |
| Amgen INC. | $14.03 | 2021 | |
| Genentech USA, INC. | $14.00 | 2021 | |
| Adlon Therapeutics L.P. | $13.68 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.81 | 2019 | |
| Bioventus LLC | $12.79 | 2019 | |
| Novartis Pharmaceuticals Corporation | $12.30 | 2019 | |
| Shire North American Group INC | $10.90 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Feaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.